Published in JAMA on September 09, 2009
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease | NCT00804583
Gene Modifiers of Cystic Fibrosis Lung Disease | NCT00037765
The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev (2012) 1.95
Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci (2010) 1.87
Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet (2014) 1.70
Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J (2012) 1.17
Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet (2013) 1.10
The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med (2012) 1.07
Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol (2010) 0.99
Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol (2012) 0.98
Genetic modifiers of cystic fibrosis-related diabetes. Diabetes (2013) 0.96
Serotonin transporter gene polymorphisms and brain function during emotional distraction from cognitive processing in posttraumatic stress disorder. BMC Psychiatry (2011) 0.95
The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulm Med (2012) 0.92
Disease-modifying genes and monogenic disorders: experience in cystic fibrosis. Appl Clin Genet (2014) 0.88
Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol (2013) 0.88
Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 0.84
Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol (2015) 0.84
Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One (2015) 0.83
Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros (2012) 0.83
Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ (2012) 0.82
Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci (2014) 0.81
Gastrointestinal Manifestations of Cystic Fibrosis. Dig Dis Sci (2015) 0.81
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. Can J Gastroenterol Hepatol (2015) 0.80
An update on laboratory diagnosis of liver inherited diseases. Biomed Res Int (2013) 0.80
A marker associated with increased risk for severe liver disease in cystic fibrosis. Clin Genet (2010) 0.78
Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol (2016) 0.78
Liver disease in cystic fibrosis: an update. Hepat Mon (2013) 0.77
CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol (2012) 0.77
Extensive molecular analysis suggested the strong genetic heterogeneity of idiopathic chronic pancreatitis. Mol Med (2016) 0.76
Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors. Prz Gastroenterol (2013) 0.75
Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol (2017) 0.75
Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol (2016) 0.75
Cystic fibrosis-related liver disease: a single-center experience. Pediatr Rep (2011) 0.75
Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr (2015) 0.75
Cystic fibrosis papers of the year 2009. J R Soc Med (2010) 0.75
Cystic Fibrosis Associated with Worse Survival After Liver Transplantation. Dig Dis Sci (2015) 0.75
Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis. United European Gastroenterol J (2016) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum (1953) 10.06
Liver cirrhosis. Lancet (2008) 6.11
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology (2002) 2.74
Mechanisms of liver fibrosis. Clin Chim Acta (2005) 2.09
Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.04
On the use of population attributable fraction to determine sample size for case-control studies of gene-environment interaction. Epidemiology (2003) 1.82
Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology (1993) 1.79
Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol (2004) 1.79
Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr (1994) 1.76
Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology (2002) 1.62
Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest (2008) 1.57
Cystic fibrosis-associated liver disease: a population-based study. J Pediatr (2004) 1.55
Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol (2004) 1.53
End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med (2003) 1.52
Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res (2006) 1.30
Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res (2000) 1.29
Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology (1998) 1.19
Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis (2001) 1.16
Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology (2007) 1.15
Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet (2008) 1.12
Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet (2003) 1.11
PI S and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi Arch Chest Dis (2007) 1.11
RE: "simple estimation of population attributable risk from case-control studies". Am J Epidemiol (1978) 1.08
Liver disease in cystic fibrosis. Curr Opin Pulm Med (2007) 1.06
Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol (2000) 1.03
Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr (2006) 1.01
Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep (2004) 0.97
The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet (2001) 0.95
Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics (1999) 0.94
Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol (1997) 0.92
Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. Am J Med Genet (2001) 0.92
Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol (1999) 0.92
Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol (2003) 0.89
Gene modifiers in pediatrics: application to cystic fibrosis. Adv Pediatr (2004) 0.87
Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology (2000) 0.87
Risk factors for the development of cystic fibrosis related liver disease. Hepatology (2003) 0.83
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat (2002) 5.43
Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med (2006) 5.37
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr (2008) 5.19
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
Theoretical and experimental comparisons of gene expression indexes for oligonucleotide arrays. Bioinformatics (2002) 4.85
Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med (2002) 4.75
Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet (2002) 4.62
BIPES, a cost-effective high-throughput method for assessing microbial diversity. ISME J (2010) 4.52
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet (2008) 4.35
Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med (2003) 4.33
Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics (2005) 4.27
Robustness of the BMP morphogen gradient in Drosophila embryonic patterning. Nature (2002) 4.21
Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation (2007) 4.17
Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med (2007) 4.03
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials (2002) 3.41
Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA (2006) 3.26
Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr (2005) 3.26
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet (2011) 3.02
Genetic defects in ciliary structure and function. Annu Rev Physiol (2007) 2.94
DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. Am J Respir Crit Care Med (2006) 2.92
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology (2010) 2.82
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. J Pediatr (2002) 2.75
Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. Genet Med (2009) 2.71
A powerful and flexible approach to the analysis of RNA sequence count data. Bioinformatics (2011) 2.49
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med (2002) 2.41
Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A (2002) 2.38
Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med (2006) 2.34
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis (2002) 2.26
Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. Am J Respir Crit Care Med (2005) 2.25
Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med (2012) 2.25
MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet (2008) 2.24
Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder. J Pediatr Gastroenterol Nutr (2011) 2.20
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol (2008) 2.18
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet (2012) 2.14
Comparison of a Brassica oleracea genetic map with the genome of Arabidopsis thaliana. Genetics (2003) 2.13
Estimating odds ratios in genome scans: an approximate conditional likelihood approach. Am J Hum Genet (2008) 2.12
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Deletions and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein arm defects. Am J Hum Genet (2009) 2.10
Development of the gastrointestinal endoscopy competency assessment tool for pediatric colonoscopy (GiECAT KIDS). J Pediatr Gastroenterol Nutr (2014) 2.06
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature (2009) 2.05
Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am J Pathol (2005) 2.05
Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome). Nat Genet (2005) 2.04
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol (2010) 2.01
Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. Eur J Hum Genet (2008) 2.01
Shwachman-Diamond syndrome: report from an international conference. J Pediatr (2002) 1.99
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr (2011) 1.95
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros (2011) 1.93
Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr (2012) 1.91
A common variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet (2009) 1.91
Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. Am J Hum Genet (2013) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr (2005) 1.87
Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr (2010) 1.86